Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
T BieberJacob Pontoppidan ThyssenKristian ReichE L SimpsonN KatohAntonio TorreloM De Bruin-WellerD ThaciR BissonnetteM GooderhamJ WeismanF NunesD BrinkerM IssaK HolzwarthM GamaloE RiedlJ JanesPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
This integrated safety analysis in patients with moderate-to-severe AD confirms the established safety profile of baricitinib.